What You Should Know:
- ARTBIO, Inc., a leader in developing targeted alpha radioligand therapies (ARTs) for cancer, and Nucleus RadioPharma Inc., a pioneer in radiopharmaceutical development and manufacturing, announced today a strategic collaboration to propel ARTBIO's clinical trials forward.
Nucleus to Manufacture ARTBIO's Lead Therapy Candidate
This agreement signifies a significant step for ARTBIO. Nucleus will manufacture ARTBIO's 212Pb-radiolabeled therapies for its
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Every Cure and BioPhy Partner to Repurpose Existing Drugs Faster with AI
What You Should Know:
- BioPhy, an AI drug development company, and Every Cure, a non-profit dedicated to unlocking the potential of existing drugs for new uses, today announced a strategic partnership to revolutionize drug repurposing through artificial intelligence (AI).
- The partnership follows Every Cure's recent funding from the Advanced Research Projects Agency for Health (ARPA-H). A successful pilot using AI led to the identification of potential treatments for diseases like sickle
Read More
Faster Drug Discovery: Yseop & AWS Unveils GenAI Tool for Biopharma R&D
What You Should Know:
· Yseop, a world-leading Artificial Intelligence (AI) software company and pioneer in Generative AI, has announced today the development of an enhanced Generative AI application tailored for the Biopharma industry, with support from Amazon Web Services (AWS).
· A member of the AWS Partner Network (APN), Yseop has strategically utilized AWS since its inception, leveraging its robust security and scalability to
Read More
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis
What You Should Know:
- Quest Diagnostics today announced it will acquire key assets of PathAI Diagnostics, including its state-of-the-art digital pathology laboratory in Memphis, Tennessee.
- As part of the acquisition, this facility will become Quest's AI and digital R&D center, supporting its pathology businesses, AmeriPath, and Dermpath Diagnostics.
Digital Pathology and AI Integration
Quest will license PathAI's AISight™ digital pathology system and AI
Read More
G1 Therapeutics and Pepper Bio Ink Global License Agreement for Lerociclib
What You Should Know:
- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding the Asia-Pacific region) for lerociclib for all indications outside acute radiation syndrome (ARS).
- As Pepper Bio’s first in-licensed therapeutic, lerociclib is a potent and selective
Read More
Genomics plc & GSK Partner to Optimize Clinical Trials with Genetic Risk Testing
What You Should Know:
- Genomics plc, a leader in polygenic risk score (PRS) technology, and pharmaceutical giant GSK inks a new collaboration to explore the potential of PRS for optimizing clinical trial design.
- The innovative approach could revolutionize the way researchers select patients and ultimately lead to faster development of new treatments.
Unlocking the Power of Genetics for Clinical Trials
Genomics plc brings its expertise in PRS technology to the table.
Read More
Deciphex & Novartis Partner on AI-Powered Pathology for Drug Discovery
What You Should Know:
- Deciphex, a leading digital pathology company based in Dublin, Ireland, has announced a collaborative effort with Novartis, a prominent multinational pharmaceutical corporation.
- The strategic partnership focuses on developing innovative artificial intelligence (AI) solutions aimed at revolutionizing preclinical pathology assessments within the drug discovery and development process.
Optimizing Preclinical Pathology with AI
The collaboration
Read More
COTA & Sanofi Partner to Leverage Real-World Data and AI to Accelerate Cancer Trials
What You Should Know:
- COTA, a leading real-world data (RWD) and analytics company in oncology, has announced a new collaboration with Sanofi.
- The strategic partnership aims to leverage RWD and artificial intelligence (AI) to accelerate clinical trials specifically focused on multiple myeloma, a cancer affecting white blood cells. The findings from this partnership have the potential to significantly impact future clinical trial designs for multiple myeloma.
Unlocking
Read More
Isospec Analytics Secures $1.9M to Transform Molecular Identification
What You Should Know:
- When developing new drugs, nutritional products, or pesticides, it’s critical that unknown molecules are identified correctly. But accurate identification is a lengthy process and all too often unsuccessful, leading to failed regulatory processes, or worse, consumer health being put in danger.
- Isospec Analytics
Read More
JAPAC Drug Development: Navigating Safety & Regulatory Requirements
The biopharmaceutical market within the Japan and Asia-Pacific (JAPAC) region has grown consistently since 2010, specifically for emerging biopharmas (EBPs). In fact, in 2018, 80% of all biopharma pipeline projects in JAPAC were EBPs, accounting for 75% of the total clinical trial volume in the region. This growth benefits contract research organizations, pharma organizations and patients alike, but several factors must be considered for drug development safety and regulatory operations in JAPAC
Read More
